Evidence map›Paper›PMID 34617674›Full record

ArticleCancer medicine2021

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer.

Kazutaka Fujita, Masayuki Nakayama, Masafumi Sata, Yoshiaki Nagai, Shu Hisata, Naoko Mato, Takuji Suzuki, Masashi Bando, Nobuyuki Hizawa, Koichi Hagiwara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kazutaka FujitaDepartment of Pulmonary Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID 0000-0003-4010-6806
Masayuki NakayamaDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Masafumi SataDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Yoshiaki NagaiDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Shu HisataDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Naoko MatoDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Takuji SuzukiDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Masashi BandoDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Nobuyuki HizawaDepartment of Pulmonary Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Koichi HagiwaraDivision of Pulmonary Medicine, Department of Internal Medicine, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan.
Jichi Medical University · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBronchoscopy is a minimally invasive procedure for establishing the diagnosis of lung cancer. It sometimes fails to obtain tissue samples but readily collects cytological samples.

methodsWe developed PNA-LNA dual-PCR (PLDP), which amplified mutant sequences by a high-fidelity DNA polymerase in the presence of a peptide nucleic acid (PNA) oligomer having a wild-type sequence. Mutations are detected either by locked nucleic acid (LNA) probes for quick detection of a limited number of mutations, which are EGFR, KRAS, and BRAF mutations in the current study, or by direct sequencing for a comprehensive screening. In a total of 233 lung cancer samples, the results for cytological samples by PLDP were compared with those for tissue samples by cobas® EGFR mutation test (cobas) or by the PNA-LNA PCR clamp method (P-LPC). Moreover, the performance of PLDP using cell-free DNA (cfDNA) was investigated.

resultsPeptide nucleic acid-LNA dual-PCR was able to detect each synthesized mutant sequence with high sensitivity. PLDP detected EGFR mutations in 80 out of 149 clinical samples, while the cobas or the P-LPC detected in 66 matched. The correctness of PLDP was confirmed both by clinical response and by the results of sequencing using a next-generation sequencer. PLDP detected mutations from cfDNA in approximately 70% of patients who harbors mutations in the tumor.

conclusionsPeptide nucleic acid-LNA dual-PCR exhibited an excellent performance, even using cytological samples. PLDP is applicable for the investigation of cfDNA. The combination of bronchoscopy and PLDP is attractive and will expand the utility of bronchoscopy in clinical practice.

Indexed as

BronchoscopyCell-Free Nucleic AcidsErbB ReceptorsHumansLung NeoplasmsMutationNeoplasm StagingNucleic Acid Amplification TechniquesPeptide Nucleic AcidsPolymerase Chain ReactionProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Sensitivity and SpecificitySequence Analysis, DNABRAF protein, humanCell-Free Nucleic AcidsEGFR protein, humanErbB ReceptorsKRAS protein, humanPeptide Nucleic AcidsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)cell-free DNAcytological samplesEGFR mutationlung cancersecondary mutation

Identifiers

PMID34617674
PMCPMC8633228
OpenAlexW3204158970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.